Chest:可以**预测非小细胞肺癌完全切除后复发风险的列线图

2018-05-13 xiangting MedSci原创

这些用户友好的列线图可以根据临床病理特征精确地预测NSCLC患者完全切除后部位特异性复发。这可以帮助临床医师制定个性化的术后随访计划。

目前关于非小细胞肺癌NSCLC)完全切除术后的最佳随访策略尚未达成共识。这项研究的目的是开发基于网络的列线图,以精确地预测NSCLC患者术后特定部位的复发,并指导包括何时随访和进行什么检查的个体化监测策略。

研究人员调查了2017年在复旦大学上海癌症中心(发展队列)接受完全手术切除的NSCLC患者(鳞状细胞癌和非鳞状浸润性腺癌)的复发类型,并开发了基于Cox回归的特定部位复发风险的网络临床病理预测模型。分析中使用的变量包括性别、年龄、吸烟史、肿瘤大小、肿瘤组织学、淋巴血管侵犯(LVI)、脏层胸膜侵犯(VPI)和病理TNM分期。使用来自上海胸科医院的一个3308例独立NSCLC患者队列进行外部验证。

列线图开发队列和外部验证队列用于预测总体复发、胸部复发、腹部复发、颈部复发、脑复发和骨复发的Harrell's C统计值分别为0.743和0.748,0.728和0.703,0.760和0.749,0.779和0.757,0.787和0.784,0.777和0.739。校准图显示列线图预测的3年无复发生存率(RFS)与实际3年RFS之间的一致性最佳。

这些用户友好的列线图可以根据临床病理特征精确地预测NSCLC患者完全切除后部位特异性复发。这可以帮助临床医师制定个性化的术后随访计划。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1905500, encodeId=0f061905500b0, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jan 29 02:20:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059709, encodeId=18452059e094c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Feb 25 04:20:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051145, encodeId=0f6120511450e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 09 15:20:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929486, encodeId=518619294860c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 07 18:20:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981409, encodeId=ba4b1981409f8, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Oct 08 00:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1905500, encodeId=0f061905500b0, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jan 29 02:20:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059709, encodeId=18452059e094c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Feb 25 04:20:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051145, encodeId=0f6120511450e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 09 15:20:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929486, encodeId=518619294860c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 07 18:20:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981409, encodeId=ba4b1981409f8, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Oct 08 00:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1905500, encodeId=0f061905500b0, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jan 29 02:20:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059709, encodeId=18452059e094c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Feb 25 04:20:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051145, encodeId=0f6120511450e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 09 15:20:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929486, encodeId=518619294860c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 07 18:20:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981409, encodeId=ba4b1981409f8, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Oct 08 00:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1905500, encodeId=0f061905500b0, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jan 29 02:20:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059709, encodeId=18452059e094c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Feb 25 04:20:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051145, encodeId=0f6120511450e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 09 15:20:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929486, encodeId=518619294860c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 07 18:20:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981409, encodeId=ba4b1981409f8, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Oct 08 00:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]
    2018-10-07 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=1905500, encodeId=0f061905500b0, content=<a href='/topic/show?id=0eb34259ea1' target=_blank style='color:#2F92EE;'>#复发风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42597, encryptionId=0eb34259ea1, topicName=复发风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca20190, createdName=wushaoling, createdTime=Tue Jan 29 02:20:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2059709, encodeId=18452059e094c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Mon Feb 25 04:20:00 CST 2019, time=2019-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051145, encodeId=0f6120511450e, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Sep 09 15:20:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929486, encodeId=518619294860c, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sun Oct 07 18:20:00 CST 2018, time=2018-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1981409, encodeId=ba4b1981409f8, content=<a href='/topic/show?id=15a8319384a' target=_blank style='color:#2F92EE;'>#列线图#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31938, encryptionId=15a8319384a, topicName=列线图)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Mon Oct 08 00:20:00 CST 2018, time=2018-10-08, status=1, ipAttribution=)]

相关资讯

2018年V3版 NCCN非小细胞肺癌指南更新要点解读

该文对 2018 年 V3 版《NCCN 非小细胞肺癌诊治指南》进行解读。与 2017 年 V9 版《NCCN 非小细胞肺癌诊治指南》相比,新版指南基于最新的循证医学证据,以分子分型和靶向治疗进展为主,规范了病理评估原则、分子检测方法、靶向耐药后续治疗,以及驱动基因阳性患者的免疫治疗选择等,并更新了分期系统,有助于更高效、更精准地指导临床实践。

NCCN临床实践指南:非小细胞肺癌(2018.V4)

2018年4月,美国国家综合癌症网络(NCCN)发布了非小细胞肺癌指南2018年第4版,指南主要内容涉及: 指南更新摘要 肺癌的预防和筛查 肺癌的临床表现和风险评估 初始评估和临床分期 各期肺癌的评估和治疗 完成确定治疗后监测 复发和转移性疾病的治疗 转移性疾病的系统治疗 病理检查原则 手术治疗原则 放射治疗原则 新辅助化疗方案与辅助治疗 放射治疗和化疗 晚期或转移性疾病的系统治疗 幸存者照护 基

PLos One:miR-133b高表达与非小细胞肺癌中使用厄洛替尼作为二三线治疗的疗效较好相关

肿瘤中miR-133b表达水平检测有助于识别预后较好并可能从使用厄洛替尼作为二三线治疗中受益的NSCLC患者。

JCO:Osimertinib比化疗有利于改善晚期非小细胞肺癌患者的状态

在评估新的肿瘤治疗策略的总临床获益时,患者报告的结局数据很重要。JCO近期发表了一篇文章,评估接受Osimertinib或化疗治疗的晚期非小细胞肺癌患者报告的症状区别。

PD-L1/ CTLA-4免疫联合治疗非小细胞肺癌未能获益

Top-line数据显示与SoC相比,Imfinzi/tremelimumab联合治疗未能显示出无进展生存期(PFS)和总生存期(OS)的统计学显著的改善。但阿斯利康表示Imfinzi单药治疗与化疗相比确实显示出具有临床意义的死亡风险降低。

ROS1阳性非小细胞肺癌诊断病理专家共识

准确的分子靶标检测是NSCLC患者获取靶向治疗的前提。与ALK融合基因检测类似,目前针对ROS1融合基因的常用方法有3种:FISH、RT-PCR和免疫组织化学法。上述3种方法各有其优缺点。FISH方法为美国国家综合癌症网络(NCCN)指南推荐的检测ROS1融合基因的检测方法,但价格昂贵,操作规范要求较高,目前还没有一家公司的FISH获得FDA的批准;RT-PCR对标本质量要求较高,需专用的试剂盒进